Skip to main content
Jacobio Pharmaceuticals Group Co., Ltd. logo

Jacobio Pharmaceuticals Group Co., Ltd. — Investor Relations & Filings

Ticker · 1167 HKEX Manufacturing
Open in API
Filings indexed 298 across all filing types
Latest filing 2026-01-05 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 1167

About Jacobio Pharmaceuticals Group Co., Ltd.

http://www.jacobiopharma.com

Jacobio Pharmaceuticals Group Co., Ltd. is a biopharmaceutical company specializing in the in-house discovery and development of innovative oncology therapies. The company is committed to providing breakthrough treatment solutions for patients by focusing its research and development pipeline on six major tumor signaling pathways: KRAS, Tumor Immunity, Tumor Metabolism, P53, RB, and MYC. Jacobio utilizes advanced drug discovery platforms, including induced allosteric mechanisms, to develop novel and improved medicines. The company primarily focuses on developing new drugs at the clinical stage, with the strategic goal of positioning its core projects among the top three globally in their respective therapeutic areas.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report movements in securities, including changes in share capital, issued shares, and treasury shares. While it tracks share movements, it is a recurring regulatory filing rather than a specific 'Share Issue' (SHA) or 'Transaction in Own Shares' (POS) announcement, as it serves as a comprehensive monthly summary of all equity movements. Therefore, it is best classified as a Regulatory Filing (RNS).
2026-01-05 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It explicitly details the repurchase of 150,000 shares by the company (Jacobio Pharmaceuticals Group Co., Ltd.) on 02 January 2026. According to the filing definitions, documents reporting the company buying back its own shares are classified as 'Transaction in Own Shares' (POS).
2026-01-02 English
INSIDE INFORMATION LICENCE AND COLLABORATION AGREEMENT WITH ASTRAZENECA FOR PAN-KRAS INHIBITOR JAB-23E73
M&A Activity Classification · 1% confidence The document is an official announcement by Jacobio Pharmaceuticals regarding a 'Licence and Collaboration Agreement' with AstraZeneca for a specific drug candidate (JAB-23E73). It details the financial terms (upfront and milestone payments), the nature of the partnership, and the strategic rationale. This type of corporate announcement regarding a significant business partnership or M&A-related licensing deal is classified as M&A Activity (TAR) within the provided schema, as it pertains to a major strategic transaction and collaboration agreement.
2025-12-21 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2025
Transaction in Own Shares Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). It details movements in the company's issued shares and treasury shares, specifically listing share repurchases conducted during the month of November 2025. Since the document primarily reports the company's activity of buying back its own shares, it falls under the 'Transaction in Own Shares' category.
2025-12-03 English
VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED UPFRONT PAYMENT UPON THE CAPITAL INCREASE AGREEMENT AND EQUITY TRANSFER AGREEMENT
Capital/Financing Update Classification · 1% confidence The document is a voluntary announcement from Jacobio Pharmaceuticals regarding the receipt of an upfront payment related to a previously disclosed Capital Increase Agreement and Equity Transfer Agreement. It details a specific financial event (receipt of funds) rather than a full financial report, proxy, or governance document. Since it pertains to financing activities and capital structure updates, it falls under the Capital/Financing Update category.
2025-12-02 English
VOLUNTARY ANNOUNCEMENT JACOBIO'S KRAS G12C AND SHP2 COMBINATION THERAPY PUBLISHED IN THE LANCET RESPIRATORY MEDICINE
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by Jacobio Pharmaceuticals regarding the publication of clinical trial results in a medical journal. It does not report financial results, dividends, or governance changes, nor is it a report publication announcement. As it is a general corporate announcement regarding business/clinical progress that does not fit into specific categories like earnings or M&A, it falls under the regulatory filing/announcement category.
2025-12-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.